The largest community of pharma leaders

Immunis.AI to Present at the BIO CEO & Investor Conference

ROYAL OAK, Mich.–()–Immunis.AI, a privately held immunogenomics company with a patented liquid biopsy platform, today announced that its President and Chief Executive Officer, Mark McDonough, will present at the BIO CEO & Investor Conference being held in New York City from February 10-11, 2020.

Date: Tuesday, February 11th

Time: 10:00 AM

Track: Diagnostics

Venue: Ziegfeld Room, New York Marriott Marquis, 1535 Broadway, New York, NY 10036

To schedule a meeting with Mark McDonough during the conference, please contact patrickthompson@ententeinc.com.

About Immunis.AI

Immunis.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology, for a truly individualized assessment. Our Intelligentia™ platform combines the power of the immune defense system, RNAseq technology and machine learning for the development of proprietary disease-specific algorithms. Our approach compares the differential gene expression patterns from two immune cells, using the patient as the control, normalizing and enhancing the signal of the underlying pathology. Intelligentia™ is a disruptive alternative, leveraging the immune system’s surveillance apparatus to overcome the limitations of cfDNA and CTC’s, enabling us to improve early stage disease detection, at the point of immune-escape, when there is the best opportunity for cure. For more information, please visit: immunis.ai

Source

Recent Articles

Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

WOBURN, Mass.--(BUSINESS WIRE)--Javelin Biotech today announces a 3-year collaboration with Pfizer...

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

DENVER & CHICAGO--(BUSINESS WIRE)-- #TollLikeReceptor--TriSalus Life Sciences announces its therapeutic clinical...

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that...

VBI Vaccines to Present at Upcoming Scientific Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage...

Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion Announces FDA Clearance of IND...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.